Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Sell these stocks now, proven algorithm says » 13:51
06/24/22
06/24
13:51
06/24/22
13:51
WRBY

Warby Parker

$14.11 /

+0.64 (+4.75%)

, DNA

Ginkgo Bioworks

$2.85 /

-0.085 (-2.90%)

, RXRX

Recursion Pharmaceuticals

$8.49 /

-0.785 (-8.46%)

, MSTR

MicroStrategy

$200.01 /

+11.95 (+6.35%)

, SWTX

SpringsWorks Therapeutics

$25.22 /

-0.38 (-1.48%)

Each week, The Fly will…

ShowHide Related Items >><<
WRBY Warby Parker
$14.11 /

+0.64 (+4.75%)

SWTX SpringsWorks Therapeutics
$25.22 /

-0.38 (-1.48%)

RXRX Recursion Pharmaceuticals
$8.49 /

-0.785 (-8.46%)

MSTR MicroStrategy
$200.01 /

+11.95 (+6.35%)

DNA Ginkgo Bioworks
$2.85 /

-0.085 (-2.90%)

WRBY Warby Parker
$14.11 /

+0.64 (+4.75%)

05/17/22 Goldman Sachs
Warby Parker downgraded to Neutral from Buy at Goldman Sachs
05/17/22 Baird
Warby Parker price target lowered to $30 from $40 at Baird
05/17/22 Citi
Warby Parker price target lowered to $29 from $41 at Citi
03/30/22 Stifel
Warby Parker initiated with a Hold at Stifel
DNA Ginkgo Bioworks
$2.85 /

-0.085 (-2.90%)

06/16/22 Jefferies
Ginkgo Bioworks price target lowered to $4.35 from $11.50 at Jefferies
05/18/22 BofA
BofA downgrades Ginkgo Bioworks to Underperform, halves target to $3
05/18/22 BofA
Ginkgo Bioworks downgraded to Underperform from Neutral at BofA
03/31/22 BTIG
Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
RXRX Recursion Pharmaceuticals
$8.49 /

-0.785 (-8.46%)

04/18/22 BofA
Recursion Pharmaceuticals downgraded to Neutral from Buy at BofA
03/04/22 SVB Securities
Recursion Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
09/21/21 Berenberg
Recursion Pharmaceuticals initiated with a Buy at Berenberg
MSTR MicroStrategy
$200.01 /

+11.95 (+6.35%)

06/16/22 Jefferies
Jefferies cuts MicroStrategy target, says does not face solvency risk
06/14/22 BTIG
MicroStrategy margin call concerns 'blown out of proportion,' says BTIG
05/23/22 Jefferies
MicroStrategy price target lowered to $215 from $225 at Jefferies
05/16/22 Jefferies
MicroStrategy does not face liquidity, solvency risk, says Jefferies
SWTX SpringsWorks Therapeutics
$25.22 /

-0.38 (-1.48%)

06/06/22 H.C. Wainwright
SpringsWorks price target lowered to $95 from $142 at H.C. Wainwright
06/06/22 H.C. Wainwright
Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
05/27/22 Wedbush
SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush
05/24/22 Goldman Sachs
SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
WRBY Warby Parker
$14.11 /

+0.64 (+4.75%)

SWTX SpringsWorks Therapeutics
$25.22 /

-0.38 (-1.48%)

RXRX Recursion Pharmaceuticals
$8.49 /

-0.785 (-8.46%)

MSTR MicroStrategy
$200.01 /

+11.95 (+6.35%)

DNA Ginkgo Bioworks
$2.85 /

-0.085 (-2.90%)

  • 29
    Sep
WRBY Warby Parker
$14.11 /

+0.64 (+4.75%)

MSTR MicroStrategy
$200.01 /

+11.95 (+6.35%)

WRBY Warby Parker
$14.11 /

+0.64 (+4.75%)

SWTX SpringsWorks Therapeutics
$25.22 /

-0.38 (-1.48%)

MSTR MicroStrategy
$200.01 /

+11.95 (+6.35%)

DNA Ginkgo Bioworks
$2.85 /

-0.085 (-2.90%)

WRBY Warby Parker
$14.11 /

+0.64 (+4.75%)

MSTR MicroStrategy
$200.01 /

+11.95 (+6.35%)

DNA Ginkgo Bioworks
$2.85 /

-0.085 (-2.90%)

Conference/Events
SpringsWorks Therapeutics participates in a conference call with JPMorgan » 12:25
06/22/22
06/22
12:25
06/22/22
12:25
SWTX

SpringsWorks Therapeutics

$23.81 /

+0.6 (+2.59%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Rama holds a conference call with CEO Islam on June 22 at 1 pm hosted by JPMorgan.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$23.81 /

+0.6 (+2.59%)

SWTX SpringsWorks Therapeutics
$23.81 /

+0.6 (+2.59%)

06/06/22 H.C. Wainwright
SpringsWorks price target lowered to $95 from $142 at H.C. Wainwright
06/06/22 H.C. Wainwright
Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
05/27/22 Wedbush
SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush
05/24/22 Goldman Sachs
SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
SWTX SpringsWorks Therapeutics
$23.81 /

+0.6 (+2.59%)

SWTX SpringsWorks Therapeutics
$23.81 /

+0.6 (+2.59%)

Conference/Events
SpringsWorks Therapeutics participates in a conference call with JPMorgan » 04:55
06/22/22
06/22
04:55
06/22/22
04:55
SWTX

SpringsWorks Therapeutics

$23.21 /

+1.38 (+6.32%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Rama holds a conference call with CEO Islam on June 22 at 1 pm hosted by JPMorgan.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$23.21 /

+1.38 (+6.32%)

SWTX SpringsWorks Therapeutics
$23.21 /

+1.38 (+6.32%)

06/06/22 H.C. Wainwright
SpringsWorks price target lowered to $95 from $142 at H.C. Wainwright
06/06/22 H.C. Wainwright
Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
05/27/22 Wedbush
SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush
05/24/22 Goldman Sachs
SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
SWTX SpringsWorks Therapeutics
$23.21 /

+1.38 (+6.32%)

SWTX SpringsWorks Therapeutics
$23.21 /

+1.38 (+6.32%)

Conference/Events
SpringsWorks Therapeutics participates in a conference call with JPMorgan » 10:15
06/21/22
06/21
10:15
06/21/22
10:15
SWTX

SpringsWorks Therapeutics

$23.48 /

+1.65 (+7.56%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Rama holds a conference call with CEO Islam on June 22 at 1 pm hosted by JPMorgan.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$23.48 /

+1.65 (+7.56%)

SWTX SpringsWorks Therapeutics
$23.48 /

+1.65 (+7.56%)

06/06/22 H.C. Wainwright
SpringsWorks price target lowered to $95 from $142 at H.C. Wainwright
06/06/22 H.C. Wainwright
Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
05/27/22 Wedbush
SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush
05/24/22 Goldman Sachs
SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
SWTX SpringsWorks Therapeutics
$23.48 /

+1.65 (+7.56%)

SWTX SpringsWorks Therapeutics
$23.48 /

+1.65 (+7.56%)

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:59
06/06/22
06/06
09:59
06/06/22
09:59
SPOT

Spotify

$113.53 /

+1.24 (+1.10%)

, CRWD

Crowdstrike

$164.16 /

+2.095 (+1.29%)

, LULU

Lululemon

$302.50 /

+1.6 (+0.53%)

, DASH

DoorDash

$69.18 /

+1.12 (+1.65%)

, ACB

Aurora Cannabis

$1.61 /

+0.01 (+0.63%)

, AXP

American Express

$169.54 /

+2.68 (+1.61%)

, TPTX

Turning Point Therapeutics

$75.05 /

+0.47 (+0.63%)

, BMY

Bristol-Myers

$75.48 /

+0.325 (+0.43%)

, PMVP

PMV Pharmaceuticals

$13.96 /

+0.12 (+0.87%)

, SWTX

SpringsWorks Therapeutics

$21.51 /

-0.11 (-0.51%)

, RVMD

Revolution Medicines

$19.17 /

+0.06 (+0.31%)

, FSTR

L.B. Foster

$13.18 /

+ (+0.00%)

, EIX

Edison International

$69.57 /

-0.12 (-0.17%)

, DNB

Dun & Bradstreet

$16.66 /

+0.21 (+1.28%)

, GDRX

GoodRx

$7.65 /

+0.085 (+1.12%)

, KR

Kroger

$52.87 /

+0.335 (+0.64%)

, BLCO

Bausch + Lomb

$16.74 /

+0.13 (+0.78%)

, SEMR

Semrush

$11.09 /

+0.05 (+0.45%)

, HNVR

Hanover Bancorp

$20.83 /

+0.11 (+0.53%)

, SLGBF

Good Natured Products

/

+

Institutional investors…

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$75.05 /

+0.47 (+0.63%)

SWTX SpringsWorks Therapeutics
$21.51 /

-0.11 (-0.51%)

SPOT Spotify
$113.53 /

+1.24 (+1.10%)

SEMR Semrush
$11.09 /

+0.05 (+0.45%)

RVMD Revolution Medicines
$19.17 /

+0.06 (+0.31%)

PMVP PMV Pharmaceuticals
$13.96 /

+0.12 (+0.87%)

LULU Lululemon
$302.50 /

+1.6 (+0.53%)

KR Kroger
$52.87 /

+0.335 (+0.64%)

GDRX GoodRx
$7.65 /

+0.085 (+1.12%)

FSTR L.B. Foster
$13.18 /

+ (+0.00%)

EIX Edison International
$69.57 /

-0.12 (-0.17%)

DNB Dun & Bradstreet
$16.66 /

+0.21 (+1.28%)

DASH DoorDash
$69.18 /

+1.12 (+1.65%)

CRWD Crowdstrike
$164.16 /

+2.095 (+1.29%)

BMY Bristol-Myers
$75.48 /

+0.325 (+0.43%)

BLCO Bausch + Lomb
$16.74 /

+0.13 (+0.78%)

AXP American Express
$169.54 /

+2.68 (+1.61%)

ACB Aurora Cannabis
$1.61 /

+0.01 (+0.63%)

SPOT Spotify
$113.53 /

+1.24 (+1.10%)

06/06/22 Raymond James
Raymond James upgrades Spotify to buy with bad news priced in
06/06/22 Raymond James
Spotify upgraded to Outperform from Market Perform at Raymond James
04/29/22 Citi
Spotify price target lowered to $165 from $240 at Citi
04/28/22 Truist
Spotify price target lowered to $150 from $210 at Truist
CRWD Crowdstrike
$164.16 /

+2.095 (+1.29%)

06/06/22 Morgan Stanley
Crowdstrike upgraded to Overweight from Equal Weight at Morgan Stanley
06/03/22 Morgan Stanley
Crowdstrike price target raised to $195 from $181 at Morgan Stanley
06/03/22 Jefferies
Crowdstrike price target raised to $215 from $200 at Jefferies
06/03/22 DA Davidson
Crowdstrike price target lowered to $235 from $280 at DA Davidson
LULU Lululemon
$302.50 /

+1.6 (+0.53%)

06/06/22 Barclays
Lululemon price target lowered to $435 from $450 at Barclays
06/06/22 Bernstein
Lululemon upgraded to Market Perform from Underperform at Bernstein
06/03/22 UBS
Lululemon price target lowered to $365 from $430 at UBS
06/03/22 Morgan Stanley
Lululemon Q1 results 'speak for themselves,' says Morgan Stanley
DASH DoorDash
$69.18 /

+1.12 (+1.65%)

06/06/22 Raymond James
DoorDash initiated with a Market Perform at Raymond James
06/03/22 DA Davidson
DoorDash price target lowered to $82 from $135 at DA Davidson
06/02/22 JMP Securities
DoorDash price target lowered to $150 from $200 at JMP Securities
06/02/22 Truist
DoorDash price target lowered to $185 from $200 at Truist
ACB Aurora Cannabis
$1.61 /

+0.01 (+0.63%)

06/06/22 Stifel
Aurora Cannabis upgraded to Hold from Sell at Stifel
05/16/22 CIBC
Aurora Cannabis price target lowered to C$3.75 from C$6.50 at CIBC
05/13/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald
04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
AXP American Express
$169.54 /

+2.68 (+1.61%)

06/06/22 Edward Jones
American Express upgraded to Buy from Hold at Edward Jones
05/12/22 Wolfe Research
Wolfe downgrades credit card issuers on 80% probability of recession
05/12/22 Wolfe Research
American Express downgraded to Peer Perform from Outperform at Wolfe Research
04/26/22 Citi
American Express price target raised to $190 from $187 at Citi
TPTX Turning Point Therapeutics
$75.05 /

+0.47 (+0.63%)

06/06/22 Cowen
Turning Point Therapeutics downgraded to Market Perform from Outperform at Cowen
06/06/22 H.C. Wainwright
Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
06/05/22 BofA
BofA keeps Buy on Bristol-Myers, raises price target to $80
06/03/22 Oppenheimer
Turning Point Therapeutics downgraded to Perform from Outperform at Oppenheimer
BMY Bristol-Myers
$75.48 /

+0.325 (+0.43%)

06/03/22 Stifel
Bristol-Myers' offer for Turning Point Therapeutics 'fair,' says Stifel
PMVP PMV Pharmaceuticals
$13.96 /

+0.12 (+0.87%)

03/02/22 Oppenheimer
Oppenheimer upgrades PMV Pharmaceuticals to Outperform with $30 price target
03/02/22 Oppenheimer
PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
09/22/21 Goldman Sachs
PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
SWTX SpringsWorks Therapeutics
$21.51 /

-0.11 (-0.51%)

06/06/22 H.C. Wainwright
SpringsWorks price target lowered to $95 from $142 at H.C. Wainwright
05/27/22 Wedbush
SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush
05/24/22 Goldman Sachs
SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
RVMD Revolution Medicines
$19.17 /

+0.06 (+0.31%)

05/20/22 BofA
BofA starts Revolution Medicines at Neutral with $24 price target
05/20/22 BofA
Revolution Medicines initiated with a Neutral at BofA
03/01/22 Stifel
Stifel upgrades Revolution Medicines, sees good entry point after pullback
FSTR L.B. Foster
$13.18 /

+ (+0.00%)

06/06/22 B. Riley
L.B. Foster downgraded to Neutral on inflation headwinds at B. Riley
06/06/22 B. Riley
L.B. Foster downgraded to Neutral from Buy at B. Riley
03/10/22 B. Riley
L.B. Foster price target lowered to $18 from $21 at B. Riley
08/04/21 B. Riley
L.B. Foster price target raised to $21 from $19 at B. Riley
EIX Edison International
$69.57 /

-0.12 (-0.17%)

06/06/22 UBS
Edison International downgraded to Neutral from Buy at UBS
06/06/22 UBS
Edison International downgraded to Neutral from Buy at UBS
05/10/22 Mizuho
Edison International downgraded to Neutral from Buy at Mizuho
05/04/22 Citi
Edison International price target raised to $79 from $67 at Citi
DNB Dun & Bradstreet
$16.66 /

+0.21 (+1.28%)

06/06/22 RBC Capital
Dun & Bradstreet downgraded to Sector Perform from Outperform at RBC Capital
06/06/22 RBC Capital
Dun & Bradstreet downgraded to Sector Perform from Outperform at RBC Capital
05/17/22 Barclays
Dun & Bradstreet price target lowered to $18 from $22 at Barclays
05/10/22 Needham
Dun & Bradstreet price target lowered to $21 from $28 at Needham
GDRX GoodRx
$7.65 /

+0.085 (+1.12%)

06/06/22 BofA
GoodRx reinstated with a Buy at BofA
06/01/22 Baird
Baird downgrades GoodRx to Neutral amid disruption at Kroger
06/01/22 Baird
GoodRx downgraded to Neutral from Outperform at Baird
05/16/22 Baird
Baird 'hypothesizing' GoodRx PBM/pharmacy issue at Kroger may be improving
KR Kroger
$52.87 /

+0.335 (+0.64%)

06/06/22 Guggenheim
Kroger price target raised to $57 from $49 at Guggenheim
06/02/22 Deutsche Bank
Kroger price target raised to $50 from $49 at Deutsche Bank
BLCO Bausch + Lomb
$16.74 /

+0.13 (+0.78%)

06/06/22 Citi
Bausch + Lomb initiated with a Buy at Citi
05/31/22 Jefferies
Bausch + Lomb initiated with a Buy at Jefferies
05/31/22 BofA
Bausch + Lomb initiated with a Buy at BofA
05/31/22 Deutsche Bank
Bausch + Lomb initiated with a Hold at Deutsche Bank
SEMR Semrush
$11.09 /

+0.05 (+0.45%)

06/06/22 Morgan Stanley
Semrush initiated with an Equal Weight at Morgan Stanley
05/12/22 KeyBanc
KeyBanc downgrades Semrush to Sector Weight on relocation, SMB risks/expenses
05/12/22 KeyBanc
Semrush downgraded to Sector Weight from Overweight at KeyBanc
05/12/22 Jefferies
Semrush price target lowered to $10 from $15 at Jefferies
HNVR Hanover Bancorp
$20.83 /

+0.11 (+0.53%)

06/06/22 Stephens
Hanover Bancorp initiated with an Overweight at Stephens
06/06/22 Piper Sandler
Hanover Bancorp initiated with an Overweight at Piper Sandler
SLGBF Good Natured Products
/

+

06/06/22 Raymond James
Good Natured Products downgraded to Market Perform from Outperform at Raymond James
12/14/21 National Bank
Good Natured Products initiated with an Outperform at National Bank
11/02/21 Raymond James
Good Natured Products price target lowered to C$1.50 from C$2 at Raymond James
10/29/21 Canaccord
Good Natured Products price target lowered to C$1.20 from C$1.90 at Canaccord
TPTX Turning Point Therapeutics
$75.05 /

+0.47 (+0.63%)

SWTX SpringsWorks Therapeutics
$21.51 /

-0.11 (-0.51%)

SPOT Spotify
$113.53 /

+1.24 (+1.10%)

SEMR Semrush
$11.09 /

+0.05 (+0.45%)

RVMD Revolution Medicines
$19.17 /

+0.06 (+0.31%)

PMVP PMV Pharmaceuticals
$13.96 /

+0.12 (+0.87%)

LULU Lululemon
$302.50 /

+1.6 (+0.53%)

KR Kroger
$52.87 /

+0.335 (+0.64%)

GDRX GoodRx
$7.65 /

+0.085 (+1.12%)

FSTR L.B. Foster
$13.18 /

+ (+0.00%)

EIX Edison International
$69.57 /

-0.12 (-0.17%)

DNB Dun & Bradstreet
$16.66 /

+0.21 (+1.28%)

DASH DoorDash
$69.18 /

+1.12 (+1.65%)

CRWD Crowdstrike
$164.16 /

+2.095 (+1.29%)

BMY Bristol-Myers
$75.48 /

+0.325 (+0.43%)

BLCO Bausch + Lomb
$16.74 /

+0.13 (+0.78%)

AXP American Express
$169.54 /

+2.68 (+1.61%)

ACB Aurora Cannabis
$1.61 /

+0.01 (+0.63%)

  • 27
    May
  • 11
    May
  • 06
    May
  • 19
    Nov
  • 19
    Aug
  • 28
    Jun
SPOT Spotify
$113.53 /

+1.24 (+1.10%)

PMVP PMV Pharmaceuticals
$13.96 /

+0.12 (+0.87%)

LULU Lululemon
$302.50 /

+1.6 (+0.53%)

KR Kroger
$52.87 /

+0.335 (+0.64%)

DASH DoorDash
$69.18 /

+1.12 (+1.65%)

CRWD Crowdstrike
$164.16 /

+2.095 (+1.29%)

BMY Bristol-Myers
$75.48 /

+0.325 (+0.43%)

BLCO Bausch + Lomb
$16.74 /

+0.13 (+0.78%)

AXP American Express
$169.54 /

+2.68 (+1.61%)

ACB Aurora Cannabis
$1.61 /

+0.01 (+0.63%)

TPTX Turning Point Therapeutics
$75.05 /

+0.47 (+0.63%)

SWTX SpringsWorks Therapeutics
$21.51 /

-0.11 (-0.51%)

SPOT Spotify
$113.53 /

+1.24 (+1.10%)

RVMD Revolution Medicines
$19.17 /

+0.06 (+0.31%)

PMVP PMV Pharmaceuticals
$13.96 /

+0.12 (+0.87%)

LULU Lululemon
$302.50 /

+1.6 (+0.53%)

KR Kroger
$52.87 /

+0.335 (+0.64%)

GDRX GoodRx
$7.65 /

+0.085 (+1.12%)

DASH DoorDash
$69.18 /

+1.12 (+1.65%)

CRWD Crowdstrike
$164.16 /

+2.095 (+1.29%)

BMY Bristol-Myers
$75.48 /

+0.325 (+0.43%)

BLCO Bausch + Lomb
$16.74 /

+0.13 (+0.78%)

AXP American Express
$169.54 /

+2.68 (+1.61%)

ACB Aurora Cannabis
$1.61 /

+0.01 (+0.63%)

SPOT Spotify
$113.53 /

+1.24 (+1.10%)

SEMR Semrush
$11.09 /

+0.05 (+0.45%)

LULU Lululemon
$302.50 /

+1.6 (+0.53%)

KR Kroger
$52.87 /

+0.335 (+0.64%)

GDRX GoodRx
$7.65 /

+0.085 (+1.12%)

DASH DoorDash
$69.18 /

+1.12 (+1.65%)

CRWD Crowdstrike
$164.16 /

+2.095 (+1.29%)

BMY Bristol-Myers
$75.48 /

+0.325 (+0.43%)

BLCO Bausch + Lomb
$16.74 /

+0.13 (+0.78%)

AXP American Express
$169.54 /

+2.68 (+1.61%)

ACB Aurora Cannabis
$1.61 /

+0.01 (+0.63%)

Recommendations
SpringsWorks price target lowered to $95 from $142 at H.C. Wainwright » 06:22
06/06/22
06/06
06:22
06/06/22
06:22
SWTX

SpringsWorks Therapeutics

$21.62 /

+1.48 (+7.35%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Robert Burns lowered the firm's price target on SpringsWorks Therapeutics to $95 from $142 and keeps a Buy rating on the shares. The analyst says nirogacestat demonstrated long-term progression-free survival in the Phase 2 National Cancer Institute trial.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$21.62 /

+1.48 (+7.35%)

SWTX SpringsWorks Therapeutics
$21.62 /

+1.48 (+7.35%)

06/06/22 H.C. Wainwright
Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
05/27/22 Wedbush
SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush
05/24/22 Goldman Sachs
SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
03/01/22 H.C. Wainwright
SpringsWorks Therapeutics price target raised to $142 from $137 at H.C. Wainwright
SWTX SpringsWorks Therapeutics
$21.62 /

+1.48 (+7.35%)

SWTX SpringsWorks Therapeutics
$21.62 /

+1.48 (+7.35%)

Downgrade
Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright » 06:18
06/06/22
06/06
06:18
06/06/22
06:18
TPTX

Turning Point Therapeutics

$74.58 /

+40.38 (+118.07%)

, BMY

Bristol-Myers

$75.17 /

+0.105 (+0.14%)

, PMVP

PMV Pharmaceuticals

$13.84 /

+0.3 (+2.22%)

, SWTX

SpringsWorks Therapeutics

$21.62 /

+1.48 (+7.35%)

, RVMD

Revolution Medicines

$19.11 /

+1.83 (+10.59%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Robert Burns downgraded Turning Point Therapeutics (TPTX) to Neutral from Buy with a price target of $76, down from $161, after the company entered into a definitive merger agreement with Bristol-Myers Squibb (BMY). In the wake of this transaction, the analyst points out to investors several other precision oncology companies in his universe that he believes could be acquisition targets for major pharma, including: PMV Pharmaceuticals (PMVP), Springworks Therapeutics (SWTX) and Revolution Medicines (RVMD).

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$74.58 /

+40.38 (+118.07%)

SWTX SpringsWorks Therapeutics
$21.62 /

+1.48 (+7.35%)

RVMD Revolution Medicines
$19.11 /

+1.83 (+10.59%)

PMVP PMV Pharmaceuticals
$13.84 /

+0.3 (+2.22%)

BMY Bristol-Myers
$75.17 /

+0.105 (+0.14%)

TPTX Turning Point Therapeutics
$74.58 /

+40.38 (+118.07%)

06/05/22 BofA
BofA keeps Buy on Bristol-Myers, raises price target to $80
06/03/22 Oppenheimer
Turning Point Therapeutics downgraded to Perform from Outperform at Oppenheimer
06/03/22 Wells Fargo
Turning Point Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
06/03/22 Stifel
Bristol-Myers' offer for Turning Point Therapeutics 'fair,' says Stifel
BMY Bristol-Myers
$75.17 /

+0.105 (+0.14%)

06/03/22 Raymond James
Raymond James downgrades Bristol-Myers on valuation after Turning Point deal
PMVP PMV Pharmaceuticals
$13.84 /

+0.3 (+2.22%)

03/02/22 Oppenheimer
Oppenheimer upgrades PMV Pharmaceuticals to Outperform with $30 price target
03/02/22 Oppenheimer
PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
09/22/21 Goldman Sachs
PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
08/19/21 Oppenheimer
PMV Pharmaceuticals initiated with a Perform at Oppenheimer
SWTX SpringsWorks Therapeutics
$21.62 /

+1.48 (+7.35%)

05/27/22 Wedbush
SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush
05/24/22 Goldman Sachs
SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
03/01/22 H.C. Wainwright
SpringsWorks Therapeutics price target raised to $142 from $137 at H.C. Wainwright
10/27/21 Wedbush
Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data
RVMD Revolution Medicines
$19.11 /

+1.83 (+10.59%)

05/20/22 BofA
BofA starts Revolution Medicines at Neutral with $24 price target
05/20/22 BofA
Revolution Medicines initiated with a Neutral at BofA
03/01/22 Stifel
Stifel upgrades Revolution Medicines, sees good entry point after pullback
03/01/22 H.C. Wainwright
Revolution Medicines price target raised to $40 from $38 at H.C. Wainwright
TPTX Turning Point Therapeutics
$74.58 /

+40.38 (+118.07%)

SWTX SpringsWorks Therapeutics
$21.62 /

+1.48 (+7.35%)

RVMD Revolution Medicines
$19.11 /

+1.83 (+10.59%)

PMVP PMV Pharmaceuticals
$13.84 /

+0.3 (+2.22%)

BMY Bristol-Myers
$75.17 /

+0.105 (+0.14%)

PMVP PMV Pharmaceuticals
$13.84 /

+0.3 (+2.22%)

BMY Bristol-Myers
$75.17 /

+0.105 (+0.14%)

TPTX Turning Point Therapeutics
$74.58 /

+40.38 (+118.07%)

SWTX SpringsWorks Therapeutics
$21.62 /

+1.48 (+7.35%)

RVMD Revolution Medicines
$19.11 /

+1.83 (+10.59%)

PMVP PMV Pharmaceuticals
$13.84 /

+0.3 (+2.22%)

BMY Bristol-Myers
$75.17 /

+0.105 (+0.14%)

BMY Bristol-Myers
$75.17 /

+0.105 (+0.14%)

Over a month ago
Recommendations
SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush » 07:46
05/27/22
05/27
07:46
05/27/22
07:46
SWTX

SpringsWorks Therapeutics

$30.81 /

-1.76 (-5.40%)

Wedbush analyst David…

Wedbush analyst David Nierengarten lowered the firm's price target on SpringsWorks Therapeutics to $50 from $110 and keeps an Outperform rating on the shares. SpringWorks presented initial data for the DREAMM5 combination study of nirogacestat + BLENREP in patients with r/r multiple myeloma, saying that patients treated with a subtherapeutic dose of BLENREP in combination with nirogacestat experienced an ORR of 38% compared to 50% for patients treated with the labeled dose of BLENREP monotherapy, Nierengarten tells investors in a research note. The analyst notes that expectations for the combination were higher, but says there should be no activity for BLENREP at the 0.95 mg/kg dose tested, and no responses at the VGPR depth.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$30.81 /

-1.76 (-5.40%)

SWTX SpringsWorks Therapeutics
$30.81 /

-1.76 (-5.40%)

05/24/22 Goldman Sachs
SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
03/01/22 H.C. Wainwright
SpringsWorks Therapeutics price target raised to $142 from $137 at H.C. Wainwright
10/27/21 Wedbush
Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data
09/08/21 JPMorgan
SpringsWorks price target raised to $105 from $97 at JPMorgan
SWTX SpringsWorks Therapeutics
$30.81 /

-1.76 (-5.40%)

SWTX SpringsWorks Therapeutics
$30.81 /

-1.76 (-5.40%)

Hot Stocks
SpringsWorks Therapeutics presents Nirogacestat Clinical Data at 2022 ASCO » 18:39
05/26/22
05/26
18:39
05/26/22
18:39
SWTX

SpringsWorks Therapeutics

$30.81 /

-1.76 (-5.40%)

, GSK

GSK plc

$44.41 /

-0.57 (-1.27%)

SpringWorks Therapeutics…

SpringWorks Therapeutics (SWTX) "announced initial clinical data from the Phase 1/2 study evaluating nirogacestat, SpringWorks' investigational gamma secretase inhibitor, in combination with BLENREP, GSK plc's (GSK) antibody drug conjugate targeting B-cell maturation agent, in patients with relapsed or refractory multiple myeloma. In addition, SpringWorks also highlighted long-term follow-up data from a Phase 2 study sponsored by the National Cancer Institute evaluating nirogacestat in patients with progressing desmoid tumors, which included follow-up on progression-free survival and long-term safety data.2 These data sets will be shared in poster sessions at the 2022 American Society of Clinical Oncology Annual Meeting, June 3-7, 2022 in Chicago. The objective of this sub-study of GSK's DREAMM-5 platform trial is to determine if low-dose BLENREP in combination with nirogacestat results in similar efficacy with an improved ocular toxicity profile compared to single-agent BLENREP at its approved dose and schedule. The study opened with a dose-exploration arm evaluating 0.95 mg/kg BLENREP Q3W combined with 100 mg BID nirogacestat dosed continuously, and subsequently moved into a cohort expansion arm. The target enrollment for the CE arm of the study is 70 patients randomized either to BLENREP 2.5mg/kg Q3W monotherapy or low-dose BLENREP plus nirogacestat combination using the same dose as the DE arm cohort. The study enrolled patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody. The poster being presented at ASCO includes data from a total of 24 patients treated with low-dose BLENREP + nirogacestat across the DE and CE cohorts and 14 patients treated with monotherapy BLENREP in the CE cohort. At the time of the March 4, 2022 data cut-off, the median of follow-up in the low-dose BLENREP plus nirogacestat DE cohort was 34.5 weeks (5-88 weeks), with durations of response exceeding one year in some patients. Data from the CE cohorts are not yet mature with a median duration of follow-up of 12 weeks available at the time of data cut-off. The CE cohorts utilized the KVA ocular toxicity grading scale; Grade 3 ocular adverse events occurred in 1/14 patients in the low-dose BLENREP plus nirogacestat combination compared to 7/14 patients in the BLENREP monotherapy arm. The DE cohort utilized the CTCAE-5 ocular toxicity grading scale; the low-dose BLENREP plus nirogacestat combination demonstrated Grade 3 ocular adverse events in 2/10 patients. At the time of data cut-off, the objective response rate of low-dose BLENREP plus nirogacestat across the DE and CE cohorts was 38%, with 17% of patients achieving a VGPR or better. The ORR of the BLENREP monotherapy control arm was 50%, with no patients achieving a VGPR or better."

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$30.81 /

-1.76 (-5.40%)

GSK GSK plc
$44.41 /

-0.57 (-1.27%)

SWTX SpringsWorks Therapeutics
$30.81 /

-1.76 (-5.40%)

05/24/22 Goldman Sachs
SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
03/01/22 H.C. Wainwright
SpringsWorks Therapeutics price target raised to $142 from $137 at H.C. Wainwright
10/27/21 Wedbush
Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data
09/08/21 JPMorgan
SpringsWorks price target raised to $105 from $97 at JPMorgan
GSK GSK plc
$44.41 /

-0.57 (-1.27%)

05/19/22 Deutsche Bank
GlaxoSmithKline price target raised to 1,750 GBp at Deutsche Bank
05/17/22 Roth Capital
Ideaya Biosciences price target raised to $46 from $42 at Roth Capital
05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
04/29/22 Barclays
GlaxoSmithKline price target raised to 1,800 GBp from 1,775 GBp at Barclays
SWTX SpringsWorks Therapeutics
$30.81 /

-1.76 (-5.40%)

GSK GSK plc
$44.41 /

-0.57 (-1.27%)

GSK GSK plc
$44.41 /

-0.57 (-1.27%)

SWTX SpringsWorks Therapeutics
$30.81 /

-1.76 (-5.40%)

GSK GSK plc
$44.41 /

-0.57 (-1.27%)

GSK GSK plc
$44.41 /

-0.57 (-1.27%)

On The Fly
Fly Intel: After-Hours Movers » 18:31
05/26/22
05/26
18:31
05/26/22
18:31
RRGB

Red Robin

$8.61 /

+0.6 (+7.49%)

, ULTA

Ulta Beauty

$378.10 /

+25.03 (+7.09%)

, DELL

Dell Technologies

$44.00 /

+0.705 (+1.63%)

, MRVL

Marvell

$56.90 /

+2.93 (+5.43%)

, ADSK

Autodesk

$191.37 /

+4.92 (+2.64%)

, ACET

Adicet Bio

$10.23 /

+0.04 (+0.39%)

, PMVP

PMV Pharmaceuticals

$13.21 /

+0.125 (+0.96%)

, ZYME

Zymeworks

$6.35 /

+0.44 (+7.45%)

, PDSB

PDS Biotechnology

$4.99 /

-0.06 (-1.19%)

, GPS

Gap

$11.15 /

+0.5 (+4.69%)

, AEO

American Eagle

$13.99 /

+0.425 (+3.13%)

, WDAY

Workday

$168.04 /

+3.57 (+2.17%)

, COST

Costco

$465.33 /

+25.32 (+5.75%)

, IOVA

Iovance Biotherapeutics

$15.11 /

+0.325 (+2.20%)

, SWTX

SpringsWorks Therapeutics

$30.81 /

-1.76 (-5.40%)

, MRTX

Mirati Therapeutics

$58.42 /

+0.43 (+0.74%)

ShowHide Related Items >><<
ZYME Zymeworks
$6.35 /

+0.44 (+7.45%)

WDAY Workday
$168.04 /

+3.57 (+2.17%)

ULTA Ulta Beauty
$378.10 /

+25.03 (+7.09%)

SWTX SpringsWorks Therapeutics
$30.81 /

-1.76 (-5.40%)

RRGB Red Robin
$8.61 /

+0.6 (+7.49%)

PMVP PMV Pharmaceuticals
$13.21 /

+0.125 (+0.96%)

PDSB PDS Biotechnology
$4.99 /

-0.06 (-1.19%)

MRVL Marvell
$56.90 /

+2.93 (+5.43%)

MRTX Mirati Therapeutics
$58.42 /

+0.43 (+0.74%)

IOVA Iovance Biotherapeutics
$15.11 /

+0.325 (+2.20%)

GPS Gap
$11.15 /

+0.5 (+4.69%)

DELL Dell Technologies
$44.00 /

+0.705 (+1.63%)

COST Costco
$465.33 /

+25.32 (+5.75%)

AEO American Eagle
$13.99 /

+0.425 (+3.13%)

ADSK Autodesk
$191.37 /

+4.92 (+2.64%)

ACET Adicet Bio
$10.23 /

+0.04 (+0.39%)

RRGB Red Robin
$8.61 /

+0.6 (+7.49%)

04/18/22 Raymond James
Red Robin downgraded to Market Perform from Outperform at Raymond James
04/18/22 Raymond James
Red Robin downgraded to Market Perform from Outperform at Raymond James
11/23/21 Benchmark
Red Robin initiated with a Buy at Benchmark
11/11/21 Raymond James
Red Robin price target lowered to $30 from $40 at Raymond James
ULTA Ulta Beauty
$378.10 /

+25.03 (+7.09%)

05/25/22 Deutsche Bank
Ulta Beauty price target lowered to $466 from $522 at Deutsche Bank
04/19/22 Piper Sandler
Ulta Beauty price target lowered to $465 from $475 at Piper Sandler
04/06/22 Piper Sandler
Piper lists winners and losers from semi-annual teen survey
03/16/22 Oppenheimer
Estee Lauder price target lowered to $300 from $350 at Oppenheimer
DELL Dell Technologies
$44.00 /

+0.705 (+1.63%)

05/25/22 Evercore ISI
Dell Technologies added to 'Tactical Outperform' list at Evercore ISI
05/25/22 JPMorgan
Dell Technologies price target lowered to $60 from $68 at JPMorgan
05/23/22 Citi
Dell Technologies price target lowered to $65 from $70 at Citi
04/19/22 KGI Securities
Dell Technologies initiated with a Neutral at KGI Securities
MRVL Marvell
$56.90 /

+2.93 (+5.43%)

05/25/22 Susquehanna
Marvell price target lowered to $90 from $105 at Susquehanna
05/23/22 B. Riley
Marvell price target lowered to $72 from $95 at B. Riley
05/23/22 UBS
Marvell price target lowered to $80 from $95 at UBS
05/20/22 Oppenheimer
Marvell price target lowered to $90 from $110 at Oppenheimer
ADSK Autodesk
$191.37 /

+4.92 (+2.64%)

05/23/22 Stifel
Autodesk price target lowered to $230 from $285 at Stifel
05/23/22 RBC Capital
Autodesk price target lowered to $255 from $295 at RBC Capital
05/23/22 Deutsche Bank
Deutsche Bank downgrades Autodesk on risk to consensus estimates
05/23/22 Deutsche Bank
Autodesk downgraded to Hold from Buy at Deutsche Bank
ACET Adicet Bio
$10.23 /

+0.04 (+0.39%)

03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
03/08/22 Truist
Adicet Bio initiated with a Buy at Truist
03/04/22 Jefferies
Adicet Bio initiated with a Buy at Jefferies
PMVP PMV Pharmaceuticals
$13.21 /

+0.125 (+0.96%)

03/02/22 Oppenheimer
Oppenheimer upgrades PMV Pharmaceuticals to Outperform with $30 price target
03/02/22 Oppenheimer
PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
09/22/21 Goldman Sachs
PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
08/19/21 Oppenheimer
PMV Pharmaceuticals initiated with a Perform at Oppenheimer
ZYME Zymeworks
$6.35 /

+0.44 (+7.45%)

05/23/22 H.C. Wainwright
Zymeworks price target lowered to $40 from $44 at H.C. Wainwright
05/09/22 Citi
Zymeworks should reject 'opportunistic' $10.50 per share offer, says Citi
05/05/22 Guggenheim
Zymeworks upgraded to Buy at Guggenheim amid low expectations
05/05/22 Guggenheim
Zymeworks upgraded to Buy from Neutral at Guggenheim
PDSB PDS Biotechnology
$4.99 /

-0.06 (-1.19%)

05/13/22 Alliance Global Partners
PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners
10/21/21 H.C. Wainwright
H.C. Wainwright says PDS Biotechnology temporary hold shouldn't spark concerns
08/12/21 H.C. Wainwright
PDS Biotechnology price target lowered to $15 from $20 at H.C. Wainwright
06/28/21 Cantor Fitzgerald
PDS Biotechnology initiated with an Overweight at Cantor Fitzgerald
GPS Gap
$11.15 /

+0.5 (+4.69%)

05/23/22 Citi
Gap downgraded to Sell from Neutral at Citi
05/17/22 UBS
Gap price target lowered to $14 from $18 at UBS
05/16/22 JPMorgan
Gap price target lowered to $11 from $14 at JPMorgan
04/25/22 Guggenheim
Guggenheim upgrades Gap to Buy with shares 70% off highs
AEO American Eagle
$13.99 /

+0.425 (+3.13%)

05/23/22 Citi
American Eagle downgraded to Neutral from Buy at Citi
05/17/22 B. Riley
American Eagle price target lowered to $32 from $41 at B. Riley
05/16/22 JPMorgan
American Eagle price target lowered to $20 from $29 at JPMorgan
04/11/22 JPMorgan
American Eagle price target lowered to $29 from $32 at JPMorgan
WDAY Workday
$168.04 /

+3.57 (+2.17%)

05/23/22 Cowen
Workday price target lowered to $250 from $310 at Cowen
05/20/22 DA Davidson
Workday price target lowered to $250 from $300 at DA Davidson
05/20/22 Barclays
Workday price target lowered to $238 from $319 at Barclays
05/18/22 Wells Fargo
Workday price target lowered to $300 from $340 at Wells Fargo
COST Costco
$465.33 /

+25.32 (+5.75%)

05/25/22 Deutsche Bank
Costco price target lowered to $525 from $530 at Deutsche Bank
05/20/22 Oppenheimer
Costco price target lowered to $500 from $645 at Oppenheimer
05/19/22 Truist
Costco price target lowered to $503 from $634 at Truist
05/19/22 Stifel
Costco price target lowered to $515 from $565 at Stifel
IOVA Iovance Biotherapeutics
$15.11 /

+0.325 (+2.20%)

04/07/22 Truist
Iovance Biotherapeutics price target lowered to $29 from $32 at Truist
04/07/22 Baird
Iovance Biotherapeutics price target raised to $34 from $30
04/06/22 Oppenheimer
Iovance 'good news' offset by timeline delay, says Oppenheimer
04/06/22 Goldman Sachs
Iovance commentary supports potency assay progress, says Goldman Sachs
SWTX SpringsWorks Therapeutics
$30.81 /

-1.76 (-5.40%)

05/24/22 Goldman Sachs
SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
03/01/22 H.C. Wainwright
SpringsWorks Therapeutics price target raised to $142 from $137 at H.C. Wainwright
10/27/21 Wedbush
Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data
09/08/21 JPMorgan
SpringsWorks price target raised to $105 from $97 at JPMorgan
MRTX Mirati Therapeutics
$58.42 /

+0.43 (+0.74%)

05/20/22 Guggenheim
Guggenheim upgrades Mirati to Buy on adagrasib's 'highly competitive profile'
05/20/22 Guggenheim
Mirati Therapeutics upgraded to Buy from Neutral at Guggenheim
05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
05/05/22 Citi
Mirati Therapeutics price target lowered to $208 from $227 at Citi
ZYME Zymeworks
$6.35 /

+0.44 (+7.45%)

WDAY Workday
$168.04 /

+3.57 (+2.17%)

ULTA Ulta Beauty
$378.10 /

+25.03 (+7.09%)

SWTX SpringsWorks Therapeutics
$30.81 /

-1.76 (-5.40%)

RRGB Red Robin
$8.61 /

+0.6 (+7.49%)

PMVP PMV Pharmaceuticals
$13.21 /

+0.125 (+0.96%)

PDSB PDS Biotechnology
$4.99 /

-0.06 (-1.19%)

MRVL Marvell
$56.90 /

+2.93 (+5.43%)

MRTX Mirati Therapeutics
$58.42 /

+0.43 (+0.74%)

IOVA Iovance Biotherapeutics
$15.11 /

+0.325 (+2.20%)

GPS Gap
$11.15 /

+0.5 (+4.69%)

DELL Dell Technologies
$44.00 /

+0.705 (+1.63%)

COST Costco
$465.33 /

+25.32 (+5.75%)

AEO American Eagle
$13.99 /

+0.425 (+3.13%)

ADSK Autodesk
$191.37 /

+4.92 (+2.64%)

ACET Adicet Bio
$10.23 /

+0.04 (+0.39%)

  • 27
    Jan
  • 08
    Dec
  • 11
    Nov
  • 15
    Jun
WDAY Workday
$168.04 /

+3.57 (+2.17%)

PMVP PMV Pharmaceuticals
$13.21 /

+0.125 (+0.96%)

GPS Gap
$11.15 /

+0.5 (+4.69%)

DELL Dell Technologies
$44.00 /

+0.705 (+1.63%)

ZYME Zymeworks
$6.35 /

+0.44 (+7.45%)

WDAY Workday
$168.04 /

+3.57 (+2.17%)

ULTA Ulta Beauty
$378.10 /

+25.03 (+7.09%)

SWTX SpringsWorks Therapeutics
$30.81 /

-1.76 (-5.40%)

RRGB Red Robin
$8.61 /

+0.6 (+7.49%)

MRVL Marvell
$56.90 /

+2.93 (+5.43%)

MRTX Mirati Therapeutics
$58.42 /

+0.43 (+0.74%)

IOVA Iovance Biotherapeutics
$15.11 /

+0.325 (+2.20%)

GPS Gap
$11.15 /

+0.5 (+4.69%)

DELL Dell Technologies
$44.00 /

+0.705 (+1.63%)

COST Costco
$465.33 /

+25.32 (+5.75%)

AEO American Eagle
$13.99 /

+0.425 (+3.13%)

ADSK Autodesk
$191.37 /

+4.92 (+2.64%)

ACET Adicet Bio
$10.23 /

+0.04 (+0.39%)

WDAY Workday
$168.04 /

+3.57 (+2.17%)

ULTA Ulta Beauty
$378.10 /

+25.03 (+7.09%)

MRVL Marvell
$56.90 /

+2.93 (+5.43%)

IOVA Iovance Biotherapeutics
$15.11 /

+0.325 (+2.20%)

GPS Gap
$11.15 /

+0.5 (+4.69%)

DELL Dell Technologies
$44.00 /

+0.705 (+1.63%)

COST Costco
$465.33 /

+25.32 (+5.75%)

AEO American Eagle
$13.99 /

+0.425 (+3.13%)

ADSK Autodesk
$191.37 /

+4.92 (+2.64%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.